Outstanding Performance in Financial Results
Carlsmed, Inc. (NASDAQ: CARL), a leading medical technology company specializing in AI-enabled personalized spine surgery solutions, has reported significant financial results for the second quarter of 2025. The company announced a revenue of $12.1 million, marking a staggering 99% year-over-year growth compared to $6.1 million in Q2 2024.
Key Growth Drivers
This remarkable revenue surge is attributed to the growing adoption of Carlsmed's unique AI-enabled aprevo technology platform, which is thriving in the spine surgery market. According to Mike Cordonnier, Chairman and CEO of Carlsmed, the increased utilization of their advanced technology in surgical procedures has shown its ability to improve patient outcomes compared to traditional methods.
Financial Highlights
Noteworthy financial highlights from Q2 2025 include:
- Gross profit reached $8.9 million with a gross margin of 73.4%, a slight decrease from 75% the previous year.
- Operating expenses totaled $15.4 million, up from $10.9 million in Q2 2024, primarily due to increased costs in research and development, sales and marketing, and general administrative expenses.
- The net loss was recorded at $6.8 million, slightly higher than the $6.3 million loss reported in the same quarter last year.
- Adjusted EBITDA loss remained consistent at $6.2 million for Q2 2025.
- As of June 30, 2025, the company maintained cash and cash equivalents of $33.5 million, bolstered by successful funding from an initial public offering that generated $93.5 million in net proceeds.
A Breakthrough in Spine Surgery
During the quarter, Carlsmed successfully completed the first personalized cervical spine surgery utilizing its aprevo technology platform, with commercial launches expected in 2026. This milestone underscores Carlsmed's commitment to innovating patient care in spine surgery.
Future Outlook
The company projects a full-year revenue forecast between $45.5 million to $47.5 million for 2025, indicating a growth rate of 67% to 75% compared to the prior year. This positive outlook is fueled by the expected adoption of their new cervical procedures, which have also received reimbursement from CMS under the New Technology Add-On Payment (NTAP) reimbursement structure effective October 1, 2025.
Upcoming Events and Webcast
Carlsmed is set to host a webcast and conference call to discuss the second quarter results and future expectations, marking a continued commitment to transparency with stakeholders. Details for accessing the call will be provided through official channels.
Company Overview
Carlsmed remains dedicated to its mission of transforming spine surgery through technology integration, aiming to advance patient outcomes while lowering healthcare costs. With a firmly established foundation in AI, the company's innovation efforts position it as a frontrunner in medical technology.
Frequently Asked Questions
What were Carlsmed's Q2 2025 earnings?
Carlsmed reported earnings of $12.1 million, showcasing a 99% increase year-over-year.
How did the company perform compared to last year?
Compared to Q2 2024, Carlsmed saw a substantial increase in revenue and a slight uptick in net loss.
What technology is Carlsmed known for?
Carlsmed is recognized for its AI-enabled personalized spine surgery solutions using the aprevo technology platform.
What financial guidance has Carlsmed provided for 2025?
The company anticipates revenue between $45.5 million and $47.5 million for the year.
When can we expect the cervical surgery technology to launch?
Carlsmed plans to commercially launch its cervical surgery technology in 2026.
